Beyond the Baggie: High Hopes for Nasal Delivery of Medical Cannabis

June 26, 2018

Published on MD+DI on June 25 by Amanda Pedersen

 

What happens when a leading medical cannabis company hooks up with a respiratory device company?

Dose-metered, nasally-delivered cannabis-based medicines, according to Columbia Care and Rhinomed. The two companies have inked a licensing agreement for the collaborative development of just such a product.

New York-based Columbia Care and Richmond, Australia-based Rhinomed plan to develop one or more new versions of Rhinomed’s existing device. The program, which will be developed in Columbia Care’s research and manufacturing facilities, will aim to optimize delivery of consistent doses of Columbia Care’s pharmaceutical-quality cannabis-based medicines via nasal administration.

The companies said nasally-delivered, dose-controlled, targeted medical cannabis formulations open up a new pathway and opportunity across a range of indications for this class of medication within the clinical and over-the-counter consumer health settings.

Rhinomed’s nasal technology platform has broad application across a range of markets. The company has commercialized two variants in sport and exercise (Turbine) and primary snoring and nasal obstruction (Mute). Columbia Care is the largest U.S.-based medical marijuana operator.

“By offering consumers and clinicians access to a range of products that solve specific unmet clinical needs, we firmly believe that we can modernise, and indeed, medicalise this market in a new and radical way,” said Rhinomed CEO Michael Johnson.

As MD+DI previously explored in this slideshow, there are a number of device-based technologies that already target the medical cannabis market.